SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending sharply upward following a recent analyst upgrade and significant price target, which is energizing discussions around its potential in the burgeoning commercial space sector. This momentum is further fueled by strong anticipation of an imminent NASA Lunar Terrain Vehicle contract award, leading to widespread speculation about a potential short squeeze. The community is actively debating the stock's perceived undervaluation compared to industry peers and its capacity for sustained growth.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending lower following its recent earnings report, despite beating revenue and EPS estimates. The significant decline is driven by investor concerns over slumping sales in China, reduced profit margins, and the impact of tariffs. The community is actively debating whether the sell-off is an overreaction or a sign of deeper fundamental issues, with many citing market share erosion to competitors and questioning leadership's strategy.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp (CCL) is trending due to the highly anticipated reinstatement of its quarterly dividend, coupled with a full-year report detailing record operational performance and investment-grade leverage metrics. The community is overwhelmingly bullish, celebrating this significant turning point as a strong indicator of renewed financial health and a robust outlook for the cruise sector. Despite initial price fluctuations, many investors view this as a clear sign of the company's return to strength and market leadership.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following its announcement of joining the U.S. Department of Energy's Genesis Mission, positioning it as a key AI infrastructure provider for government and research. This partnership is fueling strong bullish sentiment within the community, with many anticipating significant future contracts and a potential short squeeze, while others remain wary of insider selling and previous debt-related concerns. The broader AI sector's performance and recent analyst upgrades further contribute to the lively discussion around its immediate trajectory.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending following a significant $805 million government contract award for space vehicles, signaling strong demand for its national security capabilities. This substantial agreement, alongside the successful early completion of a U.S. Space Force mission, has ignited community discussions about RKLB's growth trajectory and the potential of its upcoming Neutron rocket. While many are bullish on its position in the expanding space and defense sector, some investors are also noting recent insider selling.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is actively discussed amidst investor apprehension regarding the long-term disruptive potential of autonomous vehicles from competitors like Waymo and Tesla, alongside concerns from an expanded FTC lawsuit. Despite these pressures, the community highlights Uber's strong financial performance, global platform leadership, and strategic autonomous partnerships as reasons for optimism, with many viewing the current price as a significant buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is actively trending following its announced all-stock merger with fusion power company TAE Technologies. This unexpected strategic pivot into the highly speculative fusion energy sector, aimed at future AI power demand, has sparked intense debate among market participants. Enthusiastic supporters hail it as a transformative "moonshot" with significant upside, while detractors characterize it as a high-risk speculative play, citing the company's evolving business focus and the long-term viability challenges of commercial fusion energy.

Infosys Ltd. is a digital services and consulting company, which engages in the provision of end-to-end business solutions. It operates through the following segments: Financial Services, Retail, Communication; Energy, Utilities, Resources, and Services; Manufacturing, Hi-Tech, Life Sciences, and All Other. The company was founded by Dinesh Krishnan Swamy, Senapathy Gopalakrishnan, Narayana Ramarao Nagavara Murthy, Raghavan N. S., Ashok Arora, Nandan M. Nilekani, and S. D. Shibulal on July 2, 1981 and is headquartered in Bangalore, India.

Infosys Ltd - ADR

Infosys Technologies Limited

Infosys is experiencing intense community debate following an unexplained, sharp price surge and subsequent retracement, with many speculating on coordinated buying or a "scam pump." Simultaneously, discussions are dominated by concerns over the potential disruptive impact of Agentic AI on its core IT consulting model, coupled with significant implications from a multi-billion dollar tax demand and proposed changes to H-1B visa fees, creating a complex and uncertain outlook.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending following a substantial 10-year colocation agreement for its NC-1 AI data center campus, providing significant long-term revenue visibility. This major deal for AI infrastructure capacity is driving considerable community discussion, with investors highlighting the company's position in a rapidly expanding sector amidst high demand for compute power. Market participants are anticipating enhanced growth and potential for notable stock movement.

Starfighters Space Inc

Starfighters Space Inc (FJET) is trending due to its recent IPO, which saw its shares experience significant upward movement, largely attributed to its unique position as the sole commercial entity operating sustained Mach 2 supersonic flights from NASA's Kennedy Space Center. The community is actively discussing the stock's high volatility and trading halts, with many touting its potential as a groundbreaking aerospace player, though some caution about its microcap status and perceived lack of detailed financial transparency.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month Low - Here's What Happened

Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - Should You Sell...

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen brokerages that are presently covering the company, MarketBeat...

Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low - What's Next?

Janux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low - Should You Sell...

Stempoint Capital LP Has $2.08 Million Stock Position in Janux Therapeutics, Inc. $JANX

Stempoint Capital LP lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 73.7% in the second quarter, according to the company in its most recent disclosure with the...

Janux Therapeutics (NASDAQ:JANX) Sees Large Volume Increase - Time to Buy?

Janux Therapeutics (NASDAQ:JANX) Sees Large Volume Increase - Here's What Happened...

Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 3,333 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction dated Monday, December 1st. The stock was sold at an...

Janux Therapeutics Enters Oversold Territory (JANX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

<ul class="summary-bullets"><li>Analysts flagged missing timelines and lingering questions in the JANX007 Phase 1 update.</li><li>Several firms also kept bullish ratings, calling the sell-off disproportionate.</li><li>Retail traders on Stocktwits pointed to low float dynamics and average targets far above current levels.</li></ul>Shares of Janux Therapeutics (JANX) fell nearly 50% on Tuesday after several analysts lowered their price targets following the company’s updated Phase 1 interim results for JANX007, its experimental prostate cancer drug currently being tested in patients with metastatic castration-resistant prostate cancer (mCRPC).&nbsp;Janux reported durable responses, a radiographic progression-free survival (rPFS) of 7.9–8.9 months, deep declines in prostate-specific antigen (PSA), and a manageable safety profile for cytokine release syndrome (CRS), a common immune-related side effect. Early-stage results in patients who had not previously received taxane chemotherapy were also described as “encouraging.”While the company called the update positive, analysts said the dataset raised concerns that contributed to the stock’s steep fall.<h2 class="st-heading-2">Missing Timelines And Unanswered Questions&nbsp;</h2>Cantor Fitzgerald analyst Josh Schimmer cut his price target to $150 from $200 while keeping an ‘Overweight’ rating. Schimmer said the new data answered some important questions but still left “a handful of remaining variables and blanks to fill in.” He noted that Janux did not provide timelines for when investors can expect the next clinical update or regulatory milestone.&nbsp;<h2 class="st-heading-2">Mixed Efficacy Signals&nbsp;</h2>H.C. Wainwright reduced its price target to $45 from $70 and maintained a ‘Buy’ rating. The firm said the drug’s overall effectiveness weakened on certain key measures, describing the data as “mixed.” It added that JANX007 will likely be a “show me” story, meaning investors will wait for more mature, clearer results before regaining confidence.Bank of America Securities (BofA) also called the update “admittedly mixed,” while cutting its target to $49 from $58 and keeping a ‘Buy’ rating.The firm said JANX007 is still “a viable drug with a reasonable safety profile” and may eventually show an improvement in overall survival (OS) compared with Novartis’s Pluvicto, another prostate cancer therapy. However, BofA has now pushed its expected launch to 2028 and lowered its predicted peak market share to 15% from 20%.Stifel analyst Stephen Willey echoed the mixed tone, saying there were “some positives to extract” but also ongoing questions about the dataset. He lowered his price target to $38 from $46 while keeping a ‘Buy’ rating and said the near-term catalyst calendar doesn’t set up great. Even so, Willey said he “struggles to rationalize” the drop in the stock.<h2 class="st-heading-2">Stock Slide Viewed As Excessive&nbsp;</h2>Bank of America said the stock’s decline appears “overdone,” even after adopting more cautious assumptions. Cantor Fitzgerald also said the selloff looks overdone and called the current valuation “a compelling entry point.”Clear Street lowered its price target to $32 from $80 while maintaining a ‘Buy’ rating. The firm said its cut reflects a "more pragmatic" market entry timeline and said the updated data show a “thoughtful development process.”&nbsp;<h2 class="st-heading-2">Stocktwits Traders Brace For A Sharp Rebound Rally</h2>On Stocktwits, retail sentiment for Janux was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:972/142;" src="https://news.stocktwits-cdn.com/janx_ss_png_89a213ee1a.webp" alt="janx ss.png" width="972" height="142"><figcaption>JANX sentiment and message volume as of December 2| Source: Stocktwits</figcaption></figure>One user said, “the FOMO is going to hit hard with the sideliners watching when the rebound rally kicks off.”<stembedurl>https://stocktwits.com/RainMan_17/message/637910370</stembedurl>Another bullish trader suggested the stock sits in a retail-driven sweet spot, highlighting the low float, small-cap setup, the “massive discount,” and average targets in the $70–$77 range. They also argued the drop was a “clear overreaction.”<stembedurl>https://stocktwits.com/RainMan_17/message/637909276</stembedurl><a href="https://stocktwits.com/symbol/JANX">Janux’s stock</a> has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Janux’s stock (JANX) has declined 67% so far in 2025. (Photo credit: Getty Images)

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound 

Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound.

Equity

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest JANX News

JANXJanux Therapeutics Inc